Effects of MEPARTRICIN (cas 11121-32-7) on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats

Add time:07/18/2019    Source:sciencedirect.com

The effects induced by oral administration of 0, 5 and 20 mg of meparticin kg−1of body weight for 28 days (group 1, 2 and 3, respectively) upon prostatic estrogen, androgen, α1- andβ -adrenergic receptor concentrations and on estradiol and testosterone serum levels in adult male rats were studied. The effects produced by MEPARTRICIN (cas 11121-32-7) treatments on the weight and dimension of the gland were investigated. Both mepartricin dosages induced significant decreases (P< 0.05) of the absolute and relative weights and of the dimensions of the prostate. A significant dose-dependent decrease (P< 0.05) in estradiol serum levels was observed in treated rats, whereas no significant modifications were found in testosterone serum levels. As far as prostatic steroid receptor concentrations were concerned, a significant (P< 0.05) decrease in estrogen receptor number was observed in both treated groups, whilst a significant increase (P< 0.05) of androgen receptor concentrations was recorded only in rats treated with 20 mg mepartricin kg−1. Conversely, a dose-dependent up-regulation of both prostaticα1 - and β -AR was found. Data obtained suggest that the prostaticα1 -AR expression may be strongly influenced by estrogen deprivation (mepartricin treatment), therefore the combination of estrogen suppression (mepartricin) and adrenergic suppression (α1-AR blockers) may be suggested as a possible pharmacotherapeutic strategy for the treatment of benign prostatic hyperplasia.

We also recommend Trading Suppliers and Manufacturers of MEPARTRICIN (cas 11121-32-7). Pls Click Website Link as below: cas 11121-32-7 suppliers

Prev:Removal of organic pollutants using polysulfone ultrafiltration membrane containing polystyrene silicomolybdate (cas 11121-25-8) nanoparticles: Case study: Borg El Arab area
Next:Role of MEPARTRICIN (cas 11121-32-7) in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial)